@luna113445's Wegovy journey claims, fact-checked

What did @luna113445 actually say?

Nothing about GLP-1 medications. At all. The transcript is song lyrics, not a weight loss testimonial. Lines like "too many bad bitches" and "I'm bad shit in ratchet" are not claims about semaglutide, appetite suppression, or anything remotely clinical. There is no medical content here to fact-check in the traditional sense.

The video is tagged with #wegovy and #glp1, which is almost certainly how it surfaced in a health content review. But hashtags do not equal claims. The creator appears to be lip-syncing or performing a track, possibly as part of a personal "journey" post, but nothing in the spoken words addresses GLP-1 therapy, dosing, side effects, or outcomes. This matters because context-free hashtag use can still mislead viewers scrolling a health-tagged feed.

Does the science back this up?

There is no scientific claim in this video to evaluate. That is the honest answer. The lyrics contain no assertions about body weight, metabolism, drug efficacy, or health outcomes that could be tested against published research.

That said, since this video lives in the GLP-1 content space by virtue of its tags, it is worth noting what the actual science on semaglutide looks like. The STEP 1 trial (Wilding et al., 2021, New England Journal of Medicine) found that weekly 2.4mg semaglutide produced an average 14.9% body weight reduction over 68 weeks in adults with obesity, compared to 2.4% with placebo. The SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine) found tirzepatide achieved up to 22.5% mean weight loss at the highest dose. These are the benchmarks for anyone evaluating GLP-1 content. This video contributes nothing to that conversation.

What did they get wrong (or right)?

There is nothing to correct medically. But there is something worth flagging editorially: tagging a non-informational video with clinical drug names like #wegovy and #glp1 places it inside a health information ecosystem where people are actively searching for guidance on a prescription medication.

This is not unique to this creator. GLP-1 hashtags have become lifestyle identifiers as much as medical ones. Research on health misinformation on TikTok, including work by Basch et al. (2022, Journal of Medical Internet Research) on health content patterns, shows that incidental co-mingling of entertainment and health-tagged content increases exposure to non-evidence-based material in medical search contexts. The creator did not make false health claims. But the tagging pattern is worth understanding for anyone using social platforms to research medications.

What should you actually know?

If you found this video by searching GLP-1 or Wegovy content, you deserve actual information. Semaglutide (Wegovy) is an FDA-approved GLP-1 receptor agonist for chronic weight management in adults with a BMI of 30 or higher, or 27 or higher with at least one weight-related condition. It works by mimicking a gut hormone that regulates appetite and slows gastric emptying.

Common side effects include nausea, vomiting, diarrhea, and constipation, particularly during dose escalation. The FDA label includes a boxed warning about thyroid C-cell tumors observed in rodent studies. Compounded versions of semaglutide are not equivalent to FDA-approved Wegovy or Ozempic and carry different regulatory standards. Anyone considering GLP-1 therapy should talk to a licensed clinician, not source guidance from hashtag-adjacent content.

• GLP-1 receptor agonists require a prescription and medical supervision.
• Results vary significantly by individual, adherence, and lifestyle factors.
• Stopping the medication is associated with weight regain in most patients (Wilding et al., 2022, Diabetes, Obesity and Metabolism).